Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy IMV stock | 3.56

Own IMV stock in just a few minutes.

Posted

Fact checked

IMV Inc is a biotechnology business based in the US. IMV shares (IMV) are listed on the NASDAQ and all prices are listed in US Dollars. IMV employs 62 staff and has a market cap (total outstanding shares value) of USD$239.2 million.

How to buy shares in IMV

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for IMV. Find the stock by name or ticker symbol: IMV. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until IMV reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$3.56, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of IMV, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of IMV. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

How has coronavirus impacted IMV's share price?

Since the stock market crash in March caused by coronavirus, IMV's share price has had significant negative movement.

Its last market close was USD$3.56, which is 24.35% down on its pre-crash value of USD$4.7057 and 163.70% up on the lowest point reached during the March crash when the shares fell as low as USD$1.35.

If you had bought USD$1,000 worth of IMV shares at the start of February 2020, those shares would have been worth USD$309.74 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$787.61.

IMV share price

Use our graph to track the performance of IMV stocks over time.

IMV shares at a glance

Information last updated 2020-10-19.
Latest market close USD$3.56
52-week range USD$1.35 - USD$6.82
50-day moving average USD$4.2868
200-day moving average USD$3.5484
Wall St. target price N/A
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-0.339

Buy IMV shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Vanguard
$0
Stocks, Mutual funds, ETFs, Forex
$1
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash
$0 + $0.65/contract, $1 minimum
0%
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
TD Ameritrade
$0
or $25 broker-assisted
Stocks
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy IMV stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

IMV price performance over time

Historical closes compared with the close of $3.56 from 2020-11-16

1 week (2020-11-17) 4.40%
1 month (2020-10-23) 5.33%
3 months (2020-08-24) -15.44%
6 months (2020-05-22) 0.85%
1 year (2019-11-22) 54.11%
2 years (2018-11-23) -39.25%
3 years (2017-11-24) 185.65%
5 years (2015-11-24) 564.80%

IMV financials

Gross profit TTM USD$-18,927,000
Return on assets TTM -51.4%
Return on equity TTM -153.4%
Profit margin 0%
Book value $0.186
Market capitalisation USD$239.2 million

TTM: trailing 12 months

Shorting IMV shares

There are currently 1.0 million IMV shares held short by investors – that's known as IMV's "short interest". This figure is 2.2% up from 1.0 million last month.

There are a few different ways that this level of interest in shorting IMV shares can be evaluated.

IMV's "short interest ratio" (SIR)

IMV's "short interest ratio" (SIR) is the quantity of IMV shares currently shorted divided by the average quantity of IMV shares traded daily (recently around 317089.6969697). IMV's SIR currently stands at 3.3. In other words for every 100,000 IMV shares traded daily on the market, roughly 3300 shares are currently held short.

However IMV's short interest can also be evaluated against the total number of IMV shares, or, against the total number of tradable IMV shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case IMV's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 IMV shares in existence, roughly 20 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable IMV shares, roughly 0 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against IMV.

Find out more about how you can short IMV stock.

IMV share dividends

We're not expecting IMV to pay a dividend over the next 12 months.

Have IMV's shares ever split?

IMV's shares were split on a 312:1000 basis on 10 May 2018. So if you had owned 1000 shares the day before before the split, the next day you'd have owned 312 shares. This wouldn't directly have changed the overall worth of your IMV shares – just the quantity. However, indirectly, the new 220.5% higher share price could have impacted the market appetite for IMV shares which in turn could have impacted IMV's share price.

IMV share price volatility

Over the last 12 months, IMV's shares have ranged in value from as little as $1.35 up to $6.82. A popular way to gauge a stock's volatility is its "beta".

IMV.US volatility(beta: 2.06)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while IMV's is 2.0634. This would suggest that IMV's shares are significantly more volatile than the average for this exchange and represent a higher risk.

IMV overview

IMV Inc., a clinical-stage immuno-oncology company, together with its subsidiaries, develops products based on its platform and products with a primary focus on T cell activating therapies for cancer. The company's DPX drug development platform provides a patented delivery formulation that enables controlled and prolonged exposure of antigens to the immune system. The company develops DPX-Survivac, T cell activating immunotherapy that is in Phase II clinical trials for ovarian cancer and diffuse large B-cell lymphoma. It also develops DPX-RSV, a B cell epitope peptide vaccine candidate, which has completed a Phase I clinical trial for respiratory syncytial virus; DPX-E7 an investigational immunotherapy that targets a viral protein in human papillomavirus (HPV) known as E7; and vaccine candidates for malaria and the Zika virus. IMV Inc. has collaboration and license agreements with Merck & Co., Inc., Dana-Farber Cancer Institute, Incyte Corporation, and Leidos Inc, as well as with Zoetis and The Wistar Institute; and a preclinical therapeutic research collaboration with Navidea Biopharmaceuticals, Inc. to explore the potential combinatory effect with their platform-based immunotherapies. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site